HHS Cancels mRNA Vaccine Contracts, Shifts Focus to Safer Alternatives
The Department of Health and Human Services (HHS) has announced the cancellation of 22 mRNA vaccine development contracts, amounting to about $500 million. This decision comes after a thorough review of these investments as part of the government’s Biomedical Advanced Research and Development Authority (BARDA).
HHS Secretary Robert F. Kennedy Jr. explained that the data revealed these mRNA vaccines do not effectively protect against respiratory infections like COVID-19 and the flu. He emphasized the need to redirect funds toward safer vaccine platforms that can adapt as viruses mutate.
In a brief video, Kennedy stated, “The risks associated with mRNA vaccines outweigh their benefits.” He noted that these vaccines were particularly ineffective during the COVID-19 pandemic, failing to prevent infections from variants like omicron.
Additionally, he highlighted a worrying trend known as “antigenic shift,” where vaccines can inadvertently encourage new mutations in viruses, potentially prolonging pandemics. A single mutation may render mRNA vaccines ineffective.
Despite these cancellations, ongoing mRNA research at the National Institutes of Health (NIH) will continue, and some final-stage contracts will proceed to safeguard previous taxpayer investments.
Looking ahead, HHS plans to focus on developing safer and broader vaccine strategies. Kennedy mentioned the push for whole virus vaccines and other innovative platforms that can withstand viral mutations. He reassured the public that the aim is to provide “safe, effective vaccines” for those who wish to be vaccinated, while moving past the limitations of mRNA technology.
